re: pyc - investor presentation - july 2012
If you look on slide 40 beside "Peptide drugs against intractable extracellular targets" it has under "In-House Activities & Partnerships"...
Developing new screening assays against high-value GPCRs
I contacted Nick Woolf to ask if he could give me a short description of what GPCR targeted drugs are and Phylogica's role with them are and here's his reply....
G protein-coupled receptor
GPCR-targeted drugs are one the largest drug classes. These receptors are key regulators of cell biology. Some of the high-value GPCRs have been challenging to hit with conventional small molecule or antibody drugs because of their complex biological shapes. We can tackle these ones with our Phylomers.
Number of deal discussions to date in this space = 8.
Phylogica just need one of their Phylomers in the hands of one of their partners, or indeed in their own hands, to show proof of concept (even preclinical) against a high-value challenging target. Then they will be taken out.
Regards, Tony
PYC Price at posting:
3.8¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)